SCHEMBL9906944

SCHEMBL9906944

Cc1ccc(N(C)CCO)nc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.51
HCAR3 P49019 1/20 0.45
TRPV1 Q8NER1 6/20 0.42
HDAC6 Q9UBN7 2/20 0.39
CCR1 P32246 1/20 0.39
CCR5 P51681 1/20 0.39
CCR8 P51685 1/20 0.39
DGAT1 O75907 1/20 0.37
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC9 Q9UKV0 1/20 0.36
EGFR P00533 2/20 0.36
NOS3 P29474 1/20 0.36
NOS2 P35228 1/20 0.36
PKM P14618 1/20 0.36
AOC3 Q16853 1/20 0.36
ADRA2A P08913 1/20 0.36
ADRA2B P18089 1/20 0.36
ADRA2C P18825 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13103012 0.83 HRH3 (0.47) POLBHCAR3HDAC6CCR1CCR5
SCHEMBL14554344 0.81 HCAR3 (0.41) POLBHCAR3HDAC6CCR1CCR5
SCHEMBL2790993 0.80 POLB (0.50) POLBHCAR3TRPV1DGAT1EGFR
SCHEMBL5255404 0.80 GBA1 (0.53) POLBHCAR3TRPV1DGAT1EGFR
SCHEMBL19074154 0.80 HCAR3 (0.41) POLBHCAR3TRPV1HDAC6CCR1
SCHEMBL24576251 0.79 NOS2 (0.45) POLBHCAR3HDAC6CCR1CCR5
SCHEMBL9866571 0.79 HRH3 (0.51) POLBHCAR3HDAC6CCR1CCR5
SCHEMBL11568170 0.79 PKM (0.50) POLBHCAR3HDAC6CCR1CCR5
SCHEMBL13725856 0.79 DGAT1 (0.45) HCAR3HDAC6CCR1CCR5CCR8
SCHEMBL14853401 0.79 HCAR3 (0.43) POLBHCAR3HDAC6CCR1CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140288044-A1 COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) 2014-09-25 US disclosed
US-8198456-B2 e.g. 1,4-dihydro-4-(1H-indazol-5-yl)-2,6-dimethyl-3,5-pyridinedicarbonitrile; c-Met tyrosine kinase inhibitor; antitumor agent; lung, liver, gastric and breast solid tumors; pancreatic cancer, glioma, and hepatocellular carcinoma BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-06-12 US disclosed
US-20080176833-A1 DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS BAYER INTELLECTUAL PROPERTY GMBH (DE) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140288044-A1 COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS CSNK1G1, PRKCE, PHKG1 POLB 1057/4885HCAR3 3872/4885TRPV1 2655/4885
US-20080176833-A1 DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS MET, DMPK, RET POLB 3783/4885HCAR3 3488/4885TRPV1 3275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.